FBR & Co Reaffirms “Buy” Rating for Genocea Biosciences Inc. (GNCA)
Several other research analysts have also recently issued reports on the company. Piper Jaffray Cos. decreased their price target on Genocea Biosciences from $9.00 to $12.00 and set an overweight rating for the company in a research note on Thursday, September 29th. Needham & Company LLC reissued a buy rating and issued a $15.00 price target on shares of Genocea Biosciences in a research note on Thursday, September 29th. Finally, Zacks Investment Research cut Genocea Biosciences from a buy rating to a hold rating in a research note on Wednesday, July 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $12.35.
Genocea Biosciences (NASDAQ:GNCA) traded up 1.47% on Wednesday, hitting $4.15. 13,781 shares of the stock were exchanged. Genocea Biosciences has a 52 week low of $2.56 and a 52 week high of $8.20. The company’s market cap is $117.59 million. The company’s 50-day moving average is $5.26 and its 200-day moving average is $4.72.
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative return on equity of 47.87% and a negative net margin of 5,121.17%. On average, analysts predict that Genocea Biosciences will post ($1.63) earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its position in shares of Genocea Biosciences by 0.5% in the second quarter. FMR LLC now owns 4,244,037 shares of the company’s stock valued at $17,401,000 after buying an additional 21,149 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Genocea Biosciences by 4.8% in the second quarter. Franklin Resources Inc. now owns 3,025,300 shares of the company’s stock valued at $12,404,000 after buying an additional 138,700 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Genocea Biosciences by 9.5% in the second quarter. Vanguard Group Inc. now owns 656,515 shares of the company’s stock valued at $2,691,000 after buying an additional 57,062 shares in the last quarter. AXA boosted its position in shares of Genocea Biosciences by 1.4% in the second quarter. AXA now owns 595,157 shares of the company’s stock valued at $2,440,000 after buying an additional 8,183 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Genocea Biosciences by 11.9% in the first quarter. State Street Corp now owns 291,020 shares of the company’s stock valued at $2,256,000 after buying an additional 30,920 shares in the last quarter. 56.49% of the stock is owned by institutional investors and hedge funds.
About Genocea Biosciences
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.